|
Adenoid Cystic Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
The mutational landscape of adenoid cystic carcinoma.
|
23685749 |
2013 |
|
Profound Mental Retardation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Deep sequencing reveals 50 novel genes for recessive cognitive disorders.
|
21937992 |
2011 |
|
Mental Retardation, Psychosocial
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Deep sequencing reveals 50 novel genes for recessive cognitive disorders.
|
21937992 |
2011 |
|
Mental deficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
Deep sequencing reveals 50 novel genes for recessive cognitive disorders.
|
21937992 |
2011 |
|
Intellectual Disability
|
0.300 |
Biomarker
|
group |
CTD_human |
Deep sequencing reveals 50 novel genes for recessive cognitive disorders.
|
21937992 |
2011 |
|
Hyperactive behavior
|
0.120 |
Biomarker
|
phenotype |
BEFREE |
Selective Kdm6b knockdown in the ventral hippocampus led to behavioral hyperactivity/hyperresponsiveness.
|
29605177 |
2018 |
|
Hyperactive behavior
|
0.120 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, overexpressing JMJD3 through the transfection of pcDNA3.1-JMJD3 into healthy donor CD4+ T cells increased JMJD3 enrichment and decreased H3K27me3 enrichment within the ITGAL (CD11a) promoter and up-regulated CD11a expression, leading to T and B cell hyperactivity.
|
28430662 |
2017 |
|
Hyperactive behavior
|
0.120 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Global developmental delay
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
We have identified a number of de novo alterations in the KDM6B gene via whole exome sequencing (WES) in a cohort of 12 unrelated patients with developmental delay, intellectual disability, dysmorphic facial features, and other clinical findings.
|
31124279 |
2019 |
|
Global developmental delay
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role and prospect of JMJD3 in stem cells and cancer.
|
31545292 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The histone demethylase KDM6B, also known as jumonji domain-containing protein 3 (JMJD3), is an epigenetic regulator which plays important roles in immune activation, tissue regeneration, cellular senescence and cancer metastasis.
|
30633952 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
JMJD3 has been identified as an H3K27 demethylase and its role in cancer development is context specific.
|
30696880 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KDM6B mRNA expression is downregulated in poorly differentiated high-risk neuroblastomas and upregulated in differentiated tumors, and high KDM6B expression is prognostic for better survival in neuroblastoma patients.
|
30631055 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The association between the levels of P16INK4A, lysine demethylase 6B (KDM6B) and the methylation status of histone 3 lysine 27 (H3K27) in these cell lines and the human USC tumor sample was also demonstrated.
|
30896884 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The role and prospect of JMJD3 in stem cells and cancer.
|
31545292 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The histone demethylase KDM6B, also known as jumonji domain-containing protein 3 (JMJD3), is an epigenetic regulator which plays important roles in immune activation, tissue regeneration, cellular senescence and cancer metastasis.
|
30633952 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
JMJD3 has been identified as an H3K27 demethylase and its role in cancer development is context specific.
|
30696880 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Evaluation and application of summary statistic imputation to discover new height-associated loci.
|
29782485 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study reveals an epigenetic mechanism associated with resistance to targeted therapy and demonstrates that therapeutic targeting of KDM6B-mediated IGFBP5 expression may provide a useful approach to mitigate both intrinsic and acquired resistance to the PI3K inhibitor in breast cancer.<i>Mol Cancer Ther; 17(9); 1973-83.©2018 AACR</i>.
|
29925528 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed high-throughput drug screening of epigenetic-targeted therapies across a large and diverse tumor cell line panel and uncovered the hypersensitivity of neuroblastoma cells to GSK-J4, a small-molecule dual inhibitor of lysine 27 of histone 3 (H3K27) demethylases ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), and histone demethylase Jumonji D3 (JMJD3).
|
29769286 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study reveals an epigenetic mechanism associated with resistance to targeted therapy and demonstrates that therapeutic targeting of KDM6B-mediated IGFBP5 expression may provide a useful approach to mitigate both intrinsic and acquired resistance to the PI3K inhibitor in breast cancer.<i>Mol Cancer Ther; 17(9); 1973-83.©2018 AACR</i>.
|
29925528 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous reports indicate that Jmjd3 is essential for differentiation of various cell types, such as macrophages and epidermal cells in mice, whereas Utx is involved in cancer and developmental diseases in humans and mice, as well as <i>Hox</i> regulation in zebrafish and nematodes.
|
28188179 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stratified analyses revealed that upregulated expression of JMJD3 was significantly associated with poorly differentiated tumor nuclear grade (p= 0.005) and advanced clinical stage (p= 0.043) in the bladder cancer group, while downregulated expression of JMJD3 was significantly associated with advanced clinical stage (p= 0.045) and poorly differentiated tumor nuclear grade (p= 0.011) in the RCC group.
|
27983522 |
2017 |